ClinicalTrials.gg
CompletedNCT03346434Liberty ADUpdated Jul 28, 2022Results posted

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

A Phase 2/3 interventional study of Dupilumab and Matching placebo in Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals. Completed at 48 sites in 4 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2022-07-28.

Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
202
Allocation
Non-randomized
Ages
6 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
16th of 50
202 · median 75
Started
2017
with 3 others
Phase 2/3
Only one
of the 50
Registered
16th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 16th largest by enrollment, is one of 4 that started in 2017, is the only one in phase 2/3, and was the 16th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Months to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).

Read the detailed description
  1. Part A (open-label, single-ascending-dose, sequential cohort phase 2 study):

    • Primary objective is to characterize the safety and PK of dupilumab administered as a single dose in pediatric participants, 6 months to less than 6 years of age, with severe AD.
    • Secondary objective is to evaluate the efficacy and immunogenicity of a single dose of dupilumab in participants 6 months to less than 6 years of age with severe AD.
  2. Part B (randomized, double-blind, parallel-group, placebo-controlled phase 3 study):

    • Primary objective is to demonstrate the efficacy of multiple doses of dupilumab over 16 weeks of treatment when administered concomitantly with topical corticosteroids (TCS) in pediatric participants, 6 months to less than 6 years of age, with moderate-to-severe AD.
    • Secondary objective is to assess the safety and immunogenicity of multiple doses of dupilumab over 16 weeks of treatment when administered concomitantly with TCS in participants 6 months to less than 6 years of age with moderate-to-severe AD.
03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • Eczema
04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Diagnosis of atopic dermatitis (AD) according to the American Academy of Dermatology consensus criteria at the screening visit
  • Participants with documented recent history (within 6 months before the screening visit) of inadequate response to topical AD medication(s)
  • IGA score at screening and baseline visits
  • part A: IGA = 4
  • part B: IGA ≥3
  • EASI score at screening and baseline visits
  • part A: EASI ≥21
  • part B: EASI ≥16
  • Body Surface Area (BSA) involvement at screening and baseline visits
  • part A: ≥15%
  • part B: ≥10%
  • At least 11 (of a total of 14*) applications of a topical emollient (moisturizer) during the 7 consecutive days immediately before the baseline visit (not including the day of randomization) (for part B of the study only)
  • Baseline worst scratch/itch score weekly average score for maximum scratch/itch intensity ≥4 (for part B of the study only)
  • At least 11 (of a total of 14) daily applications of low potency TCS during the 2-week TCS standardization period (beginning on day -14) leading up to the baseline visit (for part B of the study only).

Key Exclusion Criteria

  • Prior treatment with dupilumab
  • History of important side effects of low potency topical (only applicable for part B of the study)
  • Having used /immunomodulating drugs within 4 weeks before the baseline visit
  • Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the baseline visit.
  • Known or suspected immunodeficiency, known history of (HIV) infection or HIV seropositivity at the screening visit, established diagnosis of infection or HBV seropositivity at screening, established diagnosis of infection or HCV seropositivity at screening
  • History of at any time before the baseline visit
  • Diagnosed active endoparasitic infections or at high risk of these infections
  • Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study
  • Body weight \<5 kg or ≥30 kg at baseline (only applicable part B of the study)

Note: Other protocol defined Inclusion/ Exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Part A (Open label Dupilumab): Age cohorts 1 & 2

    Age cohort 1: ≥2 years old to \<6 years old Age cohort 2: ≥6 months to \<2 years old

    Drug: Dupilumab

  • Experimental
    Part B (Double-blind): Dupilumab dose 1

    The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.

    Drug: Dupilumab

  • Experimental
    Part B (Double-blind): Dupilumab dose 2

    The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.

    Drug: Dupilumab

  • Experimental
    Part B (Double-Blind): Placebo

    Drug: Matching placebo

Interventions

  • Solution for injection, subcutaneous (SC)

    Also known as: DUPIXENT®, REGN668, SAR231893

  • DrugMatching placebo

    Solution for injection, subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab

    Serum concentration of functional dupilumab was reported.

    Time frame: Post-dose on Days 1, 3, 8, 18, and 29

  2. Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab

    Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose. Cmax/dose was measured in Milligrams per Liter/Milligrams per Kilogram (\[mg/L\]/\[mg/kg\]).

    Time frame: Post-dose on Days 1, 3, 8, 18, and 29

  3. Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab

    Tmax was obtained directly from the concentration versus time curve.

    Time frame: Post-dose on Days 1, 3, 8, 18, and 29

  4. Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab

    Clast is the last measurable serum concentration of dupilumab.

    Time frame: Post-dose on Days 1, 3, 8, 18, and 29

  5. Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab

    Tlast was defined as the last time point with a measurable serum concentration of dupilumab.

    Time frame: Post-dose on Days 1, 3, 8, 18, and 29

  6. Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab

    AUClast was defined as area under the serum concentration time-curve from zero to the last measured concentration.

    Time frame: Post-dose on Days 1, 3, 8, 18, and 29

  7. Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab

    Dose normalized AUClast was calculated by AUClast/dose.

    Time frame: Post-dose on Days 1, 3, 8, 18, and 29

  8. Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

    Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE was defined as AE starting/worsening after first intake of study drug. TEAEs included participants with both SAEs and non-SAEs. Number of participants with TEAEs is reported.

    Time frame: Baseline up to Week 4

  9. Part A: Number of Participants With TEAEs by Severity According to Qualitative Toxicity Scale

    Severity of TEAEs were graded using Qualitative Toxicity Scale, as follows: Mild: Participant is aware of the event or symptom, but the event or symptom is easily tolerated; Moderate: Participant experiences sufficient discomfort to interfere with or reduce his or her usual level of activity; Severe: Significant impairment of functioning: the participant is unable to carry out his or her usual activities. Number of participants with TEAEs by severity were reported.

    Time frame: Baseline up to Week 4

  10. Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16

    The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1=almost clear; 2=mild; 3=moderate; 4=severe. A negative change from baseline indicated improvement. Percentage of participants with IGA score of '0' or '1' is reported.

    Time frame: Week 16

  11. Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16

    The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline at Week 16.

    Time frame: Week 16

Secondary outcomes

  1. Part A: Number of Participants With Serious TEAEs and Severe TEAEs

    Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Severe TEAE: significant impairment of functioning the participant is unable to carry out his or her usual activities.

    Time frame: Baseline up to Week 4

  2. Part A: Percent Change From Baseline in EASI Score at Week 4

    The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicated the worse severity of AD. A negative change from baseline indicated improvement.

    Time frame: Week 4

  3. Part A: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 4

    The SCORAD is used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.

    Time frame: Week 4

  4. Part A: Percentage of Participants With IGA Score 0 or 1 at Week 4

    The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. Percentage of participants with IGA score of '0' or '1' were reported.

    Time frame: Week 4

  5. Part A: Number of Participants With at Least One Positive Treatment-Emergent Anti-Drug Antibodies (ADA)

    Treatment boosted (TB) Response: Any post-dose positive result at least 9-fold over the baseline level when baseline is positive; Treatment emergent (TE) Response: Post-dose positive result when baseline results were negative.

    Time frame: Baseline up to Day 57

  6. Part B: Number of Participants With at Least One Serious Adverse Event (SAE) Through Week 16

    Time frame: Baseline through Week 16

  7. Part B: Number of Participants With at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infection) Through Week 16

    Time frame: Baseline through Week 16

  8. Part B: Number of Participants With at Least One Positive Treatment-Emergent ADA

    Treatment emergent (TE): Post-dose positive result when baseline results were negative.

    Time frame: Baseline up to Day 197

  9. Part B: Percent Change From Baseline in EASI Score at Week 16

    The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. A negative change from baseline indicated improvement.

    Time frame: Week 16

  10. Part B: Percent Change From Baseline in Weekly Average of Daily Worst Scratch/Itch/Numerical Rating Scale (NRS) at Week 16

    Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable. A negative change from baseline indicated improvement.

    Time frame: Week 16

  11. Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥4 Points at Week 16

    Pruritus NRS is an assessment tool used to report intensity of subject's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Subjects were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.

    Time frame: Week 16

  12. Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥3 Points at Week 16

    Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.

    Time frame: Week 16

  13. Part B: Percentage of Participants Who Achieved EASI-50 (≥50% Improvement From Baseline) at Week 16

    The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline at Week 16.

    Time frame: Week 16

  14. Part B: Percentage of Participants Who Achieved EASI-90 (≥90% Improvement From Baseline) at Week 16

    The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-90 responders were the participant who achieved ≥90% overall improvement in EASI score from baseline at Week 16.

    Time frame: Week 16

  15. Part B: Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. A negative change from baseline indicated improvement.

    Time frame: Week 16

  16. Part B: Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16

    The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). A negative change from baseline indicated improvement.

    Time frame: Week 16

  17. Part B: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

    The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.

    Time frame: Week 16

  18. Part B: Change From Baseline in Participant's Sleep Quality NRS at Week 16

    A sleep diary is completed by the parent/caregiver, included 2 questions assessing the caregiver's sleep, and 6 questions assessing the child's sleep based on caregiver observation. Sleep diary items, either alone or in combination serve as subjective measures of sleep quality, difficulty falling asleep, nighttime awakenings, and sleep duration. Sleep quality is measured using an 11-point NRS (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.

    Time frame: Week 16

  19. Part B: Change From Baseline in Participant's Skin Pain NRS at Week 16

    Skin pain was assessed by the parent/caregiver and measured using a 11-point scale (0 to 10) in which 0 indicated no pain while 10 indicated worst pain possible. A negative change from baseline indicated improvement.

    Time frame: Week 16

  20. Part B: Change From Baseline in Dermatitis Family Index (DFI) at Week 16

    DFI is a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships, and impact of helping with treatment on the primary caregiver's life. DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. A negative change from baseline indicated improvement.

    Time frame: Week 16

  21. Part B: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16

    CDLQI is a validated 10 question tool to measure impact of skin disease on QOL in children by assessing how much the skin problem has affected the subjects over past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (max. = 30, min. = 0). Higher the score, the greater the impact on QOL. A negative change from baseline indicated improvement.

    Time frame: Week 16

  22. Part B: Change From Baseline in Infants' Dermatology Quality of Life Index (IDQOL) at Week 16

    Infants' Dermatitis Quality of Life Index (IDQOL) is used to evaluate quality of life for subjects of age less than 4 years. IDQOL questionnaires were designed for infants (below the age of 4 years) with atopic dermatitis. The IDQOL was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. A negative change from baseline indicated improvement.

    Time frame: Week 16

  23. Part B: Percentage of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16

    Percentage of TCS medication-free days was calculated as the number of days that a subject used neither TCS/TCI nor system rescue therapy divided by the study days.

    Time frame: Baseline up to Week 16

  24. Part B: Mean Weekly Dose of Low Potency TCS in Grams From Baseline to Week 16

    Mean weekly dose of TCS in grams/week for low potency TCS from baseline to Week 16 is reported.

    Time frame: Baseline up to Week 16

  25. Part B: Mean Weekly Dose of TCS in Grams for Medium or High Potency TCS From Baseline to Week 16

    Mean weekly dose of TCS in grams/week for medium or high potency TCS from baseline to Week 16 is reported.

    Time frame: Baseline up to Week 16

  26. Part B: Mean Number of Caregiver Missed Work Days Through Week 16

    Mean of number of caregiver missed work days through Week 16 is reported.

    Time frame: Baseline through Week 16

07

Results

Posted Jul 28, 2022

Participant flow

This study was conducted in 2 parts: Part A and Part B; Participants who enrolled in Part A of study were not eligible to participate in Part B.

Participant flow — Overall Study
MilestonePart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Started101010107983
Completed part a101091000
Completed part b (week 16)00007683
Completed part b (week 28)000011
Completed101091011
Not completed00107882
Withdrew: Randomized in error000010
Withdrew: Withdrawal by subject001010
Withdrew: Lost to follow-up000011
Withdrew: Transitioned to ole study at week 16 (nct02612454)00007581

Outcome measures

PrimaryPart A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab

Serum concentration of functional dupilumab was reported.

Time frame:
Post-dose on Days 1, 3, 8, 18, and 29
Reported as:
Mean · Milligrams per Liter (mg/L)
Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab
Milligrams per Liter (mg/L)Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab25.2 ± 7.4449.8 ± 11.320.1 ± 6.8146.1 ± 11.1
PrimaryPart A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab

Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose. Cmax/dose was measured in Milligrams per Liter/Milligrams per Kilogram (\[mg/L\]/\[mg/kg\]).

Time frame:
Post-dose on Days 1, 3, 8, 18, and 29
Reported as:
Mean · [mg/L]/[mg/kg]
Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab
[mg/L]/[mg/kg]Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab8.39 ± 2.488.30 ± 1.896.70 ± 2.277.68 ± 1.86
PrimaryPart A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab

Tmax was obtained directly from the concentration versus time curve.

Time frame:
Post-dose on Days 1, 3, 8, 18, and 29
Reported as:
Median · Days
Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab
DaysPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg
Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab1.97 ± 1.871.95 ± 1.752.10 ± 1.801.92 ± 1.72
PrimaryPart A: Last Quantifiable Serum Concentration (Clast) of Dupilumab

Clast is the last measurable serum concentration of dupilumab.

Time frame:
Post-dose on Days 1, 3, 8, 18, and 29
Reported as:
Mean · mg/L
Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab
mg/LPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab6.64 ± 6.166.14 ± 4.695.64 ± 4.5215.1 ± 9.48
PrimaryPart A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab

Tlast was defined as the last time point with a measurable serum concentration of dupilumab.

Time frame:
Post-dose on Days 1, 3, 8, 18, and 29
Reported as:
Median · Days
Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab
DaysPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab14.8 ± 6.7926.5 ± 15.08.56 ± 6.8816.0 ± 6.95
PrimaryPart A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab

AUClast was defined as area under the serum concentration time-curve from zero to the last measured concentration.

Time frame:
Post-dose on Days 1, 3, 8, 18, and 29
Reported as:
Mean · Days*Milligrams per Liter (day*mg/L)
Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab
Days*Milligrams per Liter (day*mg/L)Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab198 ± 125622 ± 184123 ± 86.0493 ± 294
PrimaryPart A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab

Dose normalized AUClast was calculated by AUClast/dose.

Time frame:
Post-dose on Days 1, 3, 8, 18, and 29
Reported as:
Mean · [day*mg/L]/[mg/kg]
Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab
[day*mg/L]/[mg/kg]Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab66.0 ± 41.6104 ± 30.641.0 ± 28.782.1 ± 48.9
PrimaryPart A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE was defined as AE starting/worsening after first intake of study drug. TEAEs included participants with both SAEs and non-SAEs. Number of participants with TEAEs is reported.

Time frame:
Baseline up to Week 4
Reported as:
Count of participants · Participants
Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)3277
PrimaryPart A: Number of Participants With TEAEs by Severity According to Qualitative Toxicity Scale

Severity of TEAEs were graded using Qualitative Toxicity Scale, as follows: Mild: Participant is aware of the event or symptom, but the event or symptom is easily tolerated; Moderate: Participant experiences sufficient discomfort to interfere with or reduce his or her usual level of activity; Severe: Significant impairment of functioning: the participant is unable to carry out his or her usual activities. Number of participants with TEAEs by severity were reported.

Time frame:
Baseline up to Week 4
Reported as:
Count of participants · Participants
Part A: Number of Participants With TEAEs by Severity According to Qualitative Toxicity Scale
ParticipantsPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Mild1245
Moderate2022
Severe0010
PrimaryPart B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16

The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1=almost clear; 2=mild; 3=moderate; 4=severe. A negative change from baseline indicated improvement. Percentage of participants with IGA score of '0' or '1' is reported.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16
Percentage of ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 163.9 ± -0.4227.7 ± 18.45
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 23.8 · 95% CI 13.27 to 34.37
PrimaryPart B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16

The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline at Week 16.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16
Percentage of ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 1610.7 ± 3.6553.0 ± 41.74
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 42.3 · 95% CI 29.47 to 55.16
SecondaryPart A: Number of Participants With Serious TEAEs and Severe TEAEs

Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Severe TEAE: significant impairment of functioning the participant is unable to carry out his or her usual activities.

Time frame:
Baseline up to Week 4
Reported as:
Count of participants · Participants
Part A: Number of Participants With Serious TEAEs and Severe TEAEs
ParticipantsPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Participants with serious TEAEs1010
Participants with severe TEAEs0010
SecondaryPart A: Percent Change From Baseline in EASI Score at Week 4

The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicated the worse severity of AD. A negative change from baseline indicated improvement.

Time frame:
Week 4
Reported as:
Mean · Percent Change
Part A: Percent Change From Baseline in EASI Score at Week 4
Percent ChangePart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Percent Change From Baseline in EASI Score at Week 4-26.6 ± 47.37-48.7 ± 28.89-22.4 ± 42.52-43.2 ± 35.55
SecondaryPart A: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 4

The SCORAD is used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.

Time frame:
Week 4
Reported as:
Mean · Percent Change
Part A: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 4
Percent ChangePart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 4-18.6 ± 26.18-31.9 ± 17.45-22.4 ± 26.44-28.1 ± 27.84
SecondaryPart A: Percentage of Participants With IGA Score 0 or 1 at Week 4

The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. Percentage of participants with IGA score of '0' or '1' were reported.

Time frame:
Week 4
Reported as:
Number · Percentage of Participants
Part A: Percentage of Participants With IGA Score 0 or 1 at Week 4
Percentage of ParticipantsPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
Part A: Percentage of Participants With IGA Score 0 or 1 at Week 410.0 ± 0.250.0 ± 0.0010.0 ± 0.2510.0 ± 0.25
SecondaryPart A: Number of Participants With at Least One Positive Treatment-Emergent Anti-Drug Antibodies (ADA)

Treatment boosted (TB) Response: Any post-dose positive result at least 9-fold over the baseline level when baseline is positive; Treatment emergent (TE) Response: Post-dose positive result when baseline results were negative.

Time frame:
Baseline up to Day 57
Reported as:
Count of participants · Participants
Part A: Number of Participants With at Least One Positive Treatment-Emergent Anti-Drug Antibodies (ADA)
ParticipantsPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg
TB Response0010
TE Response5455
SecondaryPart B: Number of Participants With at Least One Serious Adverse Event (SAE) Through Week 16
Time frame:
Baseline through Week 16
Reported as:
Count of participants · Participants
Part B: Number of Participants With at Least One Serious Adverse Event (SAE) Through Week 16
ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Number of Participants With at Least One Serious Adverse Event (SAE) Through Week 1640
SecondaryPart B: Number of Participants With at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infection) Through Week 16
Time frame:
Baseline through Week 16
Reported as:
Count of participants · Participants
Part B: Number of Participants With at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infection) Through Week 16
ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Number of Participants With at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infection) Through Week 161910
SecondaryPart B: Number of Participants With at Least One Positive Treatment-Emergent ADA

Treatment emergent (TE): Post-dose positive result when baseline results were negative.

Time frame:
Baseline up to Day 197
Reported as:
Count of participants · Participants
Part B: Number of Participants With at Least One Positive Treatment-Emergent ADA
ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Number of Participants With at Least One Positive Treatment-Emergent ADA01
SecondaryPart B: Percent Change From Baseline in EASI Score at Week 16

The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Percent Change
Part B: Percent Change From Baseline in EASI Score at Week 16
Percent ChangePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percent Change From Baseline in EASI Score at Week 16-19.6 ± 5.13-70.0 ± 4.85
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -50.4 · 95% CI -62.38 to -38.40
SecondaryPart B: Percent Change From Baseline in Weekly Average of Daily Worst Scratch/Itch/Numerical Rating Scale (NRS) at Week 16

Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable. A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Percent Change
Part B: Percent Change From Baseline in Weekly Average of Daily Worst Scratch/Itch/Numerical Rating Scale (NRS) at Week 16
Percent ChangePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percent Change From Baseline in Weekly Average of Daily Worst Scratch/Itch/Numerical Rating Scale (NRS) at Week 16-2.2 ± 5.22-49.4 ± 5.03
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -47.1 · 95% CI -59.47 to -34.79
SecondaryPart B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥4 Points at Week 16

Pruritus NRS is an assessment tool used to report intensity of subject's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Subjects were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥4 Points at Week 16
Percentage of ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥4 Points at Week 168.9 ± 2.2548.1 ± 37.05
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 39.2 · 95% CI 26.18 to 52.27
SecondaryPart B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥3 Points at Week 16

Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥3 Points at Week 16
Percentage of ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥3 Points at Week 169.9 ± 2.5953.3 ± 42.29
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 43.3 · 95% CI 30.03 to 56.67
SecondaryPart B: Percentage of Participants Who Achieved EASI-50 (≥50% Improvement From Baseline) at Week 16

The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline at Week 16.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Part B: Percentage of Participants Who Achieved EASI-50 (≥50% Improvement From Baseline) at Week 16
Percentage of ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percentage of Participants Who Achieved EASI-50 (≥50% Improvement From Baseline) at Week 1620.2 ± 11.0968.7 ± 57.56
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 48.5 · 95% CI 35.03 to 62.00
SecondaryPart B: Percentage of Participants Who Achieved EASI-90 (≥90% Improvement From Baseline) at Week 16

The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-90 responders were the participant who achieved ≥90% overall improvement in EASI score from baseline at Week 16.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Part B: Percentage of Participants Who Achieved EASI-90 (≥90% Improvement From Baseline) at Week 16
Percentage of ParticipantsPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percentage of Participants Who Achieved EASI-90 (≥90% Improvement From Baseline) at Week 162.8 ± -1.0225.3 ± 16.39
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · Cochran-Mantel-Haenszel · p = = 0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 22.5 · 95% CI 12.37 to 32.60
SecondaryPart B: Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Percentage of Body Surface Area (BSA)
Part B: Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16
Percentage of Body Surface Area (BSA)Part B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16-10.74 ± 2.926-35.00 ± 2.815
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -24.27 · 95% CI -31.204 to -17.329
SecondaryPart B: Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16

The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Score on a Scale
Part B: Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
Score on a ScalePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16-3.8 ± 0.92-12.9 ± 0.89
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -9.1 · 95% CI -11.26 to -6.89
SecondaryPart B: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Percent Change
Part B: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16
Percent ChangePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16-16.2 ± 3.54-54.7 ± 3.39
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -38.4 · 95% CI -46.65 to -30.21
SecondaryPart B: Change From Baseline in Participant's Sleep Quality NRS at Week 16

A sleep diary is completed by the parent/caregiver, included 2 questions assessing the caregiver's sleep, and 6 questions assessing the child's sleep based on caregiver observation. Sleep diary items, either alone or in combination serve as subjective measures of sleep quality, difficulty falling asleep, nighttime awakenings, and sleep duration. Sleep quality is measured using an 11-point NRS (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.

Time frame:
Week 16
Reported as:
Least squares mean · Score on a Scale
Part B: Change From Baseline in Participant's Sleep Quality NRS at Week 16
Score on a ScalePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Change From Baseline in Participant's Sleep Quality NRS at Week 160.34 ± 0.2562.04 ± 0.251
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold significance was at 0.05 level.) · Ls mean difference: 1.70 · 95% CI 1.093 to 2.317
SecondaryPart B: Change From Baseline in Participant's Skin Pain NRS at Week 16

Skin pain was assessed by the parent/caregiver and measured using a 11-point scale (0 to 10) in which 0 indicated no pain while 10 indicated worst pain possible. A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Score on a Scale
Part B: Change From Baseline in Participant's Skin Pain NRS at Week 16
Score on a ScalePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Change From Baseline in Participant's Skin Pain NRS at Week 16-0.62 ± 0.302-3.93 ± 0.295
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold significance at 0.05 level.) · Ls mean difference: -3.31 · 95% CI -4.029 to -2.600
SecondaryPart B: Change From Baseline in Dermatitis Family Index (DFI) at Week 16

DFI is a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships, and impact of helping with treatment on the primary caregiver's life. DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Score on a Scale
Part B: Change From Baseline in Dermatitis Family Index (DFI) at Week 16
Score on a ScalePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Change From Baseline in Dermatitis Family Index (DFI) at Week 16-2.68 ± 0.839-10.48 ± 0.806
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold significance at 0.05 level.) · Ls mean difference: -7.80 · 95% CI -9.789 to -5.814
SecondaryPart B: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16

CDLQI is a validated 10 question tool to measure impact of skin disease on QOL in children by assessing how much the skin problem has affected the subjects over past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (max. = 30, min. = 0). Higher the score, the greater the impact on QOL. A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Score on a Scale
Part B: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16
Score on a ScalePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16-2.5 ± 1.66-10.0 ± 1.56
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold significance at 0.05 level.) · Ls mean difference: -7.5 · 95% CI -10.29 to -4.75
SecondaryPart B: Change From Baseline in Infants' Dermatology Quality of Life Index (IDQOL) at Week 16

Infants' Dermatitis Quality of Life Index (IDQOL) is used to evaluate quality of life for subjects of age less than 4 years. IDQOL questionnaires were designed for infants (below the age of 4 years) with atopic dermatitis. The IDQOL was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. A negative change from baseline indicated improvement.

Time frame:
Week 16
Reported as:
Least squares mean · Score on a Scale
Part B: Change From Baseline in Infants' Dermatology Quality of Life Index (IDQOL) at Week 16
Score on a ScalePart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Change From Baseline in Infants' Dermatology Quality of Life Index (IDQOL) at Week 16-1.95 ± 1.078-10.91 ± 1.159
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = < 0.0001 (Threshold significance at 0.05 level.) · Ls mean difference: -8.96 · 95% CI -11.711 to -6.202
SecondaryPart B: Percentage of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16

Percentage of TCS medication-free days was calculated as the number of days that a subject used neither TCS/TCI nor system rescue therapy divided by the study days.

Time frame:
Baseline up to Week 16
Reported as:
Median · Percentage of Days
Part B: Percentage of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16
Percentage of DaysPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Percentage of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 160.04 ± 0.00.21 ± 0.0
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = = 0.0015 (Threshold significance is at 0.05 level.)
SecondaryPart B: Mean Weekly Dose of Low Potency TCS in Grams From Baseline to Week 16

Mean weekly dose of TCS in grams/week for low potency TCS from baseline to Week 16 is reported.

Time frame:
Baseline up to Week 16
Reported as:
Least squares mean · Grams per Week
Part B: Mean Weekly Dose of Low Potency TCS in Grams From Baseline to Week 16
Grams per WeekPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Mean Weekly Dose of Low Potency TCS in Grams From Baseline to Week 1613.4 ± 1.4410.5 ± 1.39
Statistical analysis
  • Part B: Placebo + TCS vs Part B: Dupilumab 200 mg or 300 mg Q4W + TCS · ANCOVA · p = = 0.0997 (Threshold significance at 0.05 level.) · Ls mean difference: -2.9 · 95% CI -6.35 to 0.56
SecondaryPart B: Mean Weekly Dose of TCS in Grams for Medium or High Potency TCS From Baseline to Week 16

Mean weekly dose of TCS in grams/week for medium or high potency TCS from baseline to Week 16 is reported.

Time frame:
Baseline up to Week 16
Reported as:
Least squares mean · Grams per Week
Part B: Mean Weekly Dose of TCS in Grams for Medium or High Potency TCS From Baseline to Week 16
Grams per WeekPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Mean Weekly Dose of TCS in Grams for Medium or High Potency TCS From Baseline to Week 166.1 ± 1.703.0 ± 1.54
SecondaryPart B: Mean Number of Caregiver Missed Work Days Through Week 16

Mean of number of caregiver missed work days through Week 16 is reported.

Time frame:
Baseline through Week 16
Reported as:
Mean · Days
Part B: Mean Number of Caregiver Missed Work Days Through Week 16
DaysPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Part B: Mean Number of Caregiver Missed Work Days Through Week 165.05 ± 8.9752.49 ± 5.524

Adverse events

Collected over From day of first treatment up to Week 28 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg0/10 (0%)1/10 (10%)7/10 (70%)
Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg0/10 (0%)0/10 (0%)7/10 (70%)
Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg0/10 (0%)1/10 (10%)3/10 (30%)
Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg0/10 (0%)0/10 (0%)2/10 (20%)
Part B: Placebo + TCS0/78 (0%)4/78 (5.1%)45/78 (57.7%)
Part B: Dupilumab 200 mg or 300 mg Q4W + TCS0/83 (0%)0/83 (0%)29/83 (34.9%)
Most frequent serious events
Most frequent serious events
EventPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Anaphylactic reactionImmune system disorders1/100/101/100/100/780/83
HypersensitivityImmune system disorders0/100/100/100/101/780/83
Cellulitis staphylococcalInfections and infestations0/100/100/100/101/780/83
Dermatitis infectedInfections and infestations0/100/100/100/101/780/83
Staphylococcal bacteraemiaInfections and infestations0/100/100/100/101/780/83
Dermatitis atopicSkin and subcutaneous tissue disorders0/100/100/100/101/780/83
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCS
Dermatitis atopicSkin and subcutaneous tissue disorders0/101/101/100/1024/7812/83
NasopharyngitisInfections and infestations1/102/101/101/107/787/83
PyrexiaGeneral disorders2/100/101/100/107/781/83
Upper respiratory tract infectionInfections and infestations1/101/100/100/107/785/83
ImpetigoInfections and infestations1/101/101/100/106/783/83
FolliculitisInfections and infestations1/100/100/100/100/780/83
UrticariaSkin and subcutaneous tissue disorders1/101/100/100/104/781/83
ThrombocytosisBlood and lymphatic system disorders0/101/100/100/100/780/83
ConstipationGastrointestinal disorders1/100/100/100/100/782/83
DiarrhoeaGastrointestinal disorders1/101/100/100/102/781/83

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCSTotal
6 months - <2 years0010105631
≥2 years and <6 years1010007477171
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCSTotal
Female4312243973
Male67985544129
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCSTotal
Hispanic or Latino322291129
Not Hispanic or Latino78887072173
Unknown or Not Reported0000000
Investigator Global Assessment (IGA)
Investigator Global Assessment (IGA)(Participants)Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kgPart A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kgPart A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kgPart B: Placebo + TCSPart B: Dupilumab 200 mg or 300 mg Q4W + TCSTotal
IGA=3 (moderate)0000172037
IGA=4 (severe)101010106263165
08

Study locations

48 sites
  • Regeneron Investigational Site
    Birmingham, Alabama 35209, United States
  • Regeneron Investigational Site
    Gilbert, Arizona 85234, United States
  • Regeneron Investigational Site
    Long Beach, California 90808, United States
  • Regeneron Investigational site
    Los Angeles, California 90027, United States
  • Regeneron Investigational Site
    Palo Alto, California 94304, United States
  • Regeneron Investigational Site
    Rolling Hills Estates, California 90274, United States
  • Regeneron Investigational Site
    San Diego, California 92123, United States
  • Regeneron Investigational Site
    Washington, District of Columbia 20010, United States
  • Regeneron Investigational Site
    Coral Gables, Florida 33146, United States
  • Regeneron Investigational Site
    Tampa, Florida 33612-3807, United States
  • Regeneron Investigational Site
    Columbus, Georgia 31904, United States
  • Regeneron Investigational Site
    Macon, Georgia 31217, United States
  • Regeneron Investigational Site
    Sandy Springs, Georgia 39328, United States
  • Regeneron Investigational Site
    Chicago, Illinois 60611, United States
  • Regeneron Investigational Site
    Rockville, Maryland 20850, United States
  • Regeneron Investigational Site
    Boston, Massachusetts 02115, United States
  • Regeneron Investigational Site
    Ann Arbor, Michigan 48109-5314, United States
  • Regeneron Investigational Site
    Ypsilanti, Michigan 48197, United States
  • Regeneron Investigational Site
    Saint Louis, Missouri 63104-1003, United States
  • Regeneron Investigational Site
    Lincoln, Nebraska 68505, United States
  • Regeneron Investigational Site
    Hackensack, New Jersey 07601, United States
  • Regeneron Investigational Site
    Forest Hills, New York 113756, United States
  • Regeneron Investigational Site
    New York, New York 10032, United States
  • Regeneron Investigational Site
    Rochester, New York 14642, United States
  • Regeneron Investigational Site
    Portland, Oregon 97239, United States
  • Regeneron Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron Investigational Site
    Charleston, South Carolina 29425, United States
  • Regeneron Investigational Site
    North Charleston, South Carolina 29420, United States
  • Regeneron Investigational Site
    Austin, Texas 78723, United States
  • Regeneron Investigational Site
    San Antonio, Texas 78218, United States
  • Regeneron Investigational Site
    Norfolk, Virginia 23502, United States
  • Regeneron Investigational Site
    Seattle, Washington 98105, United States
  • Regeneron Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • Regeneron Investigational Site
    Osnabrück, Lower Saxony 49074, Germany
  • Regeneron Investigational site
    Muenster, North Rhine-Westphal 48149, Germany
  • Regeneron Investigational Site
    Dresden, Sachsen 01307, Germany
  • Regeneron Investigational site
    Frankfurt/ Main, 60590, Germany
  • Regeneron Investigational Site
    Kiel, 24105, Germany
  • Regeneron Investigational Site
    Muenchen, 80337, Germany
  • Regeneron Investigational site
    Muenchen, 80802, Germany
  • Regeneron Investigational Site
    Bialystok, 15-453, Poland
  • Regeneron Investigational Site
    Katowice, 40-648, Poland
  • Regeneron Investigational Site
    Krakow, 31-011, Poland
  • Regeneron Investigational Site
    Ostrowiec Swietokrzyski, 27-400, Poland
  • Regeneron Investigational Site
    Warszawa, 01-142, Poland
  • Regeneron Investigational Site
    Warszawa, 01-817, Poland
  • Regeneron Investigational Site
    Manchester, Lancashire M13 9WL, United Kingdom
  • Regeneron Investigational Site
    Sheffield, South Yorkshire S10 2TH, United Kingdom
09

References and documents

Publications

  • Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, Dubost-Brama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A; participating investigators. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140-6736(22)01539-2. PubMed 36116481 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jul 2021, 43 months.

Results were first posted in Jul 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2017
First posted
Nov 17, 2017
StartActual
Nov 30, 2017
Primary completionActual
Jul 8, 2021
CompletionActual
Jul 8, 2021
Results first posted
Jul 28, 2022
Last update
Jul 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03346434
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 30, 2017
Primary completion
Jul 8, 2021
Completion
Jul 8, 2021
Results posted
Jul 28, 2022
Last update
Jul 28, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion